Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-04
2006-04-04
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255010, C544S383000, C544S389000
Reexamination Certificate
active
07022707
ABSTRACT:
The present invention is a chemical compound of formula (I)or a pharmaceutically acceptable salts, solvates and esters thereof, wherein R1to R4, A1, A2m and n are as described in the specification.
REFERENCES:
patent: 3933802 (1976-01-01), Ferrini et al.
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 4931463 (1990-06-01), Barbier et al.
patent: 4983746 (1991-01-01), Barbier et al.
patent: 5245056 (1993-09-01), Karpf et al.
patent: 5494928 (1996-02-01), Bös
patent: 5756817 (1998-05-01), Choi et al.
patent: 5977116 (1999-11-01), Castro Pineiro et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 185 359 (1986-06-01), None
patent: 189 577 (1986-08-01), None
patent: 443 449 (1991-08-01), None
patent: 524 495 (1993-01-01), None
patent: 655 440 (1995-05-01), None
patent: 75 26228 (1977-03-01), None
patent: 2 321 890 (1977-04-01), None
patent: 2 744 449 (1997-08-01), None
patent: WO 98/30548 (1998-07-01), None
patent: WO 99/34786 (1999-07-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 00/09123 (2000-02-01), None
patent: WO 00/35922 (2000-06-01), None
Hartman et al. Chemical Abstracts, vol. 133, No. 238020, Abstract for WO 2000/051611 (Sep. 8, 2000).
Yung-Chi et al., Biochem Pharmacol, vol. 22(23), pp. 3099-3108 (1973).
Curson et al., Psychopharmacol, vol. 96, pp. 93-100 (1988).
Curson et al., European J. Pharmacol., vol. 141, pp. 429-435 (1987).
C. T. Dourish et al., Psychopharmacol., vol. 113, pp. 369-377 (1994).
A. E. Walsh et al., Psychopharmacol., vol. 116, pp. 120-122 (1994).
Sargeant et al., Psychopharmacol., vol. 133, pp. 309-312 (1997).
L. H. Tecott et al., Nature, vol. 374, pp. 542-546 (1995).
G.A.Kennett et al., Neuropharmacol., vol. 36, pp. 609-620 (1997).
D.Hoyer et al., European J.Pharmacol., vol. 118, pp. 13-23 (1985).
K. Schmuck, et al., FEBS Lett., vol. 342, pp. 85-90 (1994).
Papageorgiou, Org. Lett., vol. 2(8), pp. 1049-1051 (2000).
McKenna et al., J. of Neuroscience, vol. 9(10), pp. 3482-3490 (1989).
S. Parker, “Obesity: Trends and Treatments”, Scrip Reports (1996).
Abstract No. CA-2132887 (1995).
Abstract No. CA-2153937 (1996).
Abstract No. XP002227535 for Toldy, et al., Acta Chimica Academiae Scientiarum Hungarica., vol. 53, p. 279 (1967).
Abstract No. XP002227534 for Larkin, H., et al., Tetrahedron Letters, vol. 27, No. 24, pp. 2721-2724 (1986).
Abstract No. XP002227536 for Aicher, T., et al., Journal of Medicinal Chemistry, vol. 43, No. 2, pp. 236-249 (2000).
Hays S.J., et al., Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 33, No. 10 pp. 2916-2924 (1990).
Kawamoto, et al., Chemical Abstract vol. 118, No. 233765 (1993).
Papageorgiou, et. al., Organic letters, vol. 2, pp. 1049-1051 (Mar. 2000).
Adams David Reginald
Bentley Jonathan Mark
Davidson James Edward Paul
Dawson Claire Elizabeth
George Ashley Roger
Hoffman-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
O'Sullivan Peter
Tramaloni Dennis P.
LandOfFree
Piperazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525756